Rheumatoid Arthritis
Conversion initiative gives ‘significant’ boost to Remicade biosimilar use
An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.
Patients with later menarche, earlier menopause have higher risk for rheumatoid arthritis
Menarche after the age of 14 years, or going through menopause before 45 years of age, are among the hormonal and reproductive factors that increase the risk for rheumatoid arthritis, according to data published in RMD Open.
36-year-old man with RA with bilateral knee pain and severe valgus deformities
A 36-year-old man with seronegative rheumatoid arthritis presented to clinic for evaluation with a history of debilitating bilateral knee pain and deformity.
Machine learning predicts osteoporosis in patients with rheumatoid arthritis
Machine learning algorithms can be effective in predicting osteoporosis among patients with rheumatoid arthritis, as well as identifying new predictive factors, according to data published in Nature Scientific Reports.
Non-TNF inhibitors have higher retention rates in patients with rheumatoid arthritis
Patients with rheumatoid arthritis are increasingly receiving non-TNF inhibitors, which additionally demonstrate higher retention rates, compared with other biologics, according to data published in Nature Scientific Reports.
Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand
Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.
Autoimmune thyroid disease risk decreases after rheumatoid arthritis diagnosis
Adults have a decreased risk for developing autoimmune thyroid disease after being diagnosed with rheumatoid arthritis, with the risk even lower for those receiving disease-modifying antirheumatic drugs, according to study data.
Best rheumatology Q&As of 2023 covered Alzheimer’s, lupus in a catatonic patient
In 2023, Healio had questions, the experts had answers.
‘A great step forward’: The next wave of rheum therapies offers ‘tantalizing’ approaches
In rheumatology, the next generation of new therapies always seems to be just out of reach, or perpetually “only a few years” away. However, several novel, and not-so-novel, approaches are giving hope that the future may finally soon arrive.
Obstetric outcomes unaffected by maintaining TNF inhibition during pregnancy
SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.